Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
Belgian investor Sofina offloaded 41.78 lakh shares of Mamaearth-parent Honasa Consumer via bulk deal, capitalising on a 42% YTD rally. The exit follows Honasa's ₹135 Cr Fluence Pharma buy and its Honasa 3.0 plan targeting ₹5,500 Cr revenue and 15% EBITDA margins by FY31.
What happened
Sofina Ventures sold a 1.28% stake in Honasa Consumer for ₹177.2 Cr via bulk deal at ₹424.07/share. The sale follows Honasa's Fluence Pharma acquisition and
Key facts
- ₹177.2 Cr
- 41.78 Lakh shares
- ₹424.07/share
- 1.28% stake
- 42% YTD gain
- ₹437.90 52-week high
- ₹135 Cr Fluence acquisition
- 58% stake
- ₹5,500 Cr FY31 revenue target
- 15% EBITDA margin target
Why this matters
Post Fluence Pharma acquisition, Honasa retains M&A firepower and a clearer growth thesis, making it a more credible consolidator in beauty & personal care as legacy PE capital rotates out.
What to watch
- Bulk/block deal screens for additional Sofina or PE exits >50bps
- Promoter pledge or buyback announcements as counter-signal
- Honasa 3.0 milestone updates vs ₹5,500 Cr FY31 trajectory
- BPC sector channel checks — Nykaa BPC GMV, Plum/Sugar funding rounds
- Brokerage target price revisions in next 2 weeks
- Track Sofina's remaining shareholding disclosure post-deal and any 13D-equivalent filings
- Monitor Q3FY25 results for Mamaearth volume growth and offline GT expansion metrics
- Watch Fluence Pharma integration milestones and revenue contribution guidance
- Scan for follow-on blocks from other pre-IPO investors (Sequoia, Fireside, Stellaris)